All manuscripts must be submitted online through SAGE Track, as follows:
Accessing SAGE Track: Go to http://mc.manuscriptcentral.com/jocp. Please see the User Tutorial for Authors for complete instructions on creating an account and submitting a manuscript. For assistance, e-mail m.spraycar@verizon.net.
Uploading your article to SAGE Track: The manuscript text should be uploaded in Microsoft Word. Tables and figures can be provided in many original formats. Putting these elements in separate files helps to achieve the best resolution for the printed page, although they may also be embedded in the text. When loading figures, you will be prompted to answer questions for each one. We suggest that you select the first choice to all the questions to expedite the process. If you are unsure of a question at any time, select the “Help” button found in the top right hand section of your Web browser.
When you have completed the submission, please record the manuscript number assigned. If you need further information at any time, this number will be requested. You may log back into the system periodically to see the status of your article. From your inbox, choose “My Manuscripts.”
Contributor form (formerly the copyright transfer process): After acceptance, authors must complete the JCP Contributor Agreement, in which they agree to grant an exclusive license to publish the work to Sage Publications, while retaining the copyright for themselves. In the case of Author-Owned Works, forms are completed and submitted online according to instructions sent at the time a manuscript is accepted. Authors submitting Works for Hire must select the checkbox “Work made for hire for employer/Work done in the course of employment” and will need to collect a company signature. Then they will need to send the form as a scanned document by e-mail, per instructions at the time of acceptance. In both cases, only the corresponding author must sign and no changes can be made to the form.
Financial disclosure: Authors should disclose all financial involvements (including stock ownership or options that are unrelated to primary employment, consultancies, honoraria, research grants, and royalties) connected with the work or its sponsors, as well as all sources of support, including government and industry support. All information should appear on the title page of the submitted manuscript and match the information provided on item 2 of the contributor form, Declaration of Competing Interests and Financial Disclosure. The disclosure information will be published with accepted manuscripts as Acknowledgements. If there are no disclosures, that information will be stated as well.
Editorial content: JCP publishes original papers, editorials, commentaries, therapeutic reviews, and brief reports. Manuscripts are invited that deal with the effects of drugs in humans. These include, but are not limited to, the general categories of pharmacokinetics and drug disposition, pharmacodynamics, clinical trials and design issues, pharmacogenomics, pharmacoepidemiology and safety, and human pharmacology. A new area of emphasis for submissions is the validation and use of biomarkers in drug development. Articles should be clearly written and well organized. Priority will be given to new developments in the field.
Specific requirements: Corresponding author: One author should be designated as the corresponding author to correspond with the editorial staff, receive galley proofs, and handle reprint requests. That author’s primary affiliation, complete mailing address, telephone numbers, fax number, and e-mail address should be included.
Cover letter: In a letter, describe the submission, the category in which it belongs, and its contribution to the medical literature.
Manuscript: Manuscripts must be prepared electronically and submitted in Microsoft Word.
Title page: Include the name and address of the corresponding author, the address for reprints, and an indication of which authors, if any, are fellows of the American College of Clinical Pharmacology (FCP). The primary affiliations of all authors must be listed, as should any financial interest disclosures. Please provide 3 to 5 keywords on the title page.
Abstract: All reports except editorials and brief reports must include an abstract of 200 words or fewer.
Table and figure preparation: Figures and tables should be numbered in the order in which they are discussed in the text.
Drug nomenclature: All drugs and therapeutic agents should be referred to by their accepted generic or chemical name. The name should not be abbreviated. Code numbers should be used only when a generic name is not yet available. In that case, the chemical name and a figure giving the chemical structure of the drug are required. A proprietary/trade name may be used one time in the "Methods" section of a report to designate a particular preparation used in a study. In editorials or commentaries, the editor may elect to allow 1 parenthetical use of a trade name following the first mention of the generic name, if this is felt to be scientifically pertinent and not promotional.
Requirements for referencing analytic methods in original reports: Analytic methods that are not referenced to archived peer-reviewed publications must include specific core information, such as the detector and monitoring settings, internal standards, and assay performance parameters. Specific sample preparation details are not required.
Human subject protection: It must be explicitly stated that an investigational review board (IRB) approved the study protocol, and the specific IRB should be named in the "Methods" section. For studies with large numbers of sites, such as population pharmacokinetic studies, the editor may at her discretion append the specific sites in an online version because of space considerations. In those cases, a notation to that effect will be included in the "Methods" section of the paper.
References: Notation within the text should be in sequential numeric superscript. References should appear at the end of the manuscript using the format of the
American Medical Association Manual of Style (10th edition) and should contain all authors of the original report unless there are more than 6 authors, in which case the first 3 authors should be listed, followed by "et al."
Requirements for "Brief Reports": As above, but no abstract, fewer than 3000 words of text, and a limit of 2 (total) figures and/or tables.
Letters to the Editor: Letters for consideration may address articles previously published in JCP or issues felt to be of importance to JCP readers. Authors are urged to keep Letters to fewer than 500 words, although longer letters may be accepted at the descretion of the Editor. Letters must be submitted through SAGE Track; authors must complete a copyright transfer and financial disclosure statement, as described above.
Highlights and Book Reviews: Summaries of important papers relevant to clinical pharmacology can be sent directly to the Highlights and Book Reviews section editor or to the editorial office (
m.spraycar@verizon.net) for forwarding and subsequent consideration. Summaries should be limited to approximately 750 words. Publishers should send inquiries regarding books for possible review to the editorial office for consideration.
Supplements: Supplements are occasionally published, and the costs are borne by outside sponsors. Contents must undergo review, and final approval rests with the journal editor. More information can be obtained by contacting the editorial office or Sage Publications.
Peer Review Process. Initial review: If a manuscript is selected for review, it will be sent to at least 2 reviewers. A decision will then be sent to the author through SAGE Track, generally within 4 weeks. The review system is not blinded. The editor will recuse herself from all proceedings involving manuscripts in which there is a conflict of interest for her, and the resulting process for those manuscripts will be blinded from the editor. All attempts are made to identify potential conflicts of interest before reviewer assignment; however, reviewers should excuse themselves if an assignment with a conflict of interest is made.
Revised manuscripts: Revised manuscripts must also be submitted through SAGE Track. In the resubmission, authors must include a cover letter as well as explicit responses to reviewers’ comments in the rebuttal box in SAGE Track. Two versions of the revision must be submitted: one showing Track Changes and one without Track Changes. Revised manuscripts must be submitted within 60 days unless explicit permission for an extension is obtained from the editorial office. Other manuscripts are subject to withdrawal from the system.
Permissions: Direct quotations, tables, or illustrations that have appeared in copyrighted material must be accompanied by written permission for their use from the copyright owner (usually the publisher) and original author, along with complete information as to the source. Any photographs of identifiable persons should be accompanied by signed releases that show informed consent. Requests for permission to reproduce material that has appeared in JCP should be submitted online to the following:
http://www.sagepub.com/permissions.nav. Written requests may be sent to Sage Publications, 2455 Teller Road, Thousand Oaks, CA 91320.
Advertisements: All advertisements are reviewed for suitability of content. However, the editorial board is not aware of advertisements before their appearance in the journal.
Announcements: JCP will publish official notices of interest to the members of the American College of Clinical Pharmacology.
Reprints: Authors will receive a schedule of reprint costs with galley proofs. More information regarding reprints can be obtained from: Barbara Eisenberg, Commercial Sales Specialist, Sage Publications, 2455 Teller Road, Thousand Oaks, CA 91320, Phone: (805) 410-7763, Fax: (805) 499-8096, e-mail:
reprint@sagepub.com.
Inquiries: All inquiries regarding manuscripts that have not yet been published should be submitted by e-mail to Marjory Spraycar, editorial manager, at the following e-mail address:
m.spraycar@verizon.net or by fax to (410) 321-1456.
